Intellia, one of the first big CRISPR companies, unveiled one new approach to reaching that simple IV at a scientific conference Wednesday. The biotech used custom lipid nanoparticles — those now–famous tiny bubbles of fat — to carry CRISPR into the bone marrow of mice and edit stem cells there. After repeated dosing, the company’s scientists said they were able to edit more than enough cells to provide a functional cure for sickle cell.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,